Copyright
©The Author(s) 2019.
World J Meta-Anal. Jun 30, 2019; 7(6): 309-322
Published online Jun 30, 2019. doi: 10.13105/wjma.v7.i6.309
Published online Jun 30, 2019. doi: 10.13105/wjma.v7.i6.309
Study | Arms | Number | Period | Country | Schedule |
Casadei et al[20], 2015 | NCRT + S | 18 | 2007-2014 | Italy | 2 cycles of gemcitabine 1000 mg/m2 on days 1 and 8 every 21 d, then 45 Gy radiation with gemcitabine 50 mg/m2 twice weekly for 6 wk |
Surgery | 20 | ||||
Golcher et al[21], 2015 | NCRT + S | 33 | 2003-2009 | Germany, Switzerland | 8 Gy to 55.8 Gy (tumor) or 50.4 Gy (regional lymph nodes) radiation with gemcitabine 300 mg/m2 and cisplatin 30 mg/m2 on days 1, 8, 22, and 29 |
Surgery | 33 | ||||
Oettle et al[22,26], 2007, 2013 | S + ACT | 179 | 1998-2004 | Germany, Austria | 3 cycles of gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 wk |
Surgery | 175 | ||||
Kosuge et al[27], 2006 | S + ACT | 45 | 1992-2000 | Japan | 2 courses of cisplatin 80 mg/m2 on the first day; 5-fluorouracil 500 mg/m2 daily for the first 5 d |
Surgery | 44 | ||||
Ueno et al[24], 2009 | S + ACT | 58 | 2002-2005 | Japan | 3 cycles of gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 wk |
Surgery | 60 | ||||
Bakkevold et al[31], 1993 | S + ACT | 30 | 1984-1987 | Norway | 6 cycles of 5-fluorouracil 500 mg/m2, doxorubicin 40 mg/m2, and mitomycin C 6 mg/m2 once every 3 wk |
Surgery | 31 | ||||
Smeenk et al[8], 2007 Klinkenbijl et al[30], 1999 | S + ACDT | 110 | 1987-1995 | Europe | 2 courses of 20 Gy radiotherapy (2 Gy/d, 5 d/wk at weeks 1-2 and 5-6) and 25 mg/kg 5- fluorouracil daily for 5 d |
Surgery | 108 | ||||
Kalser et al[32], 1985 | S + ACDT | 21 | 1974-1982 | USA | 2 courses of 20 Gy (5 d a week) radiotherapy and 500 mg/m2 fluorouracil daily for 3 d |
Surgery | 22 | ||||
Van Laethem et al[23], 2010 | S + ACDT | 45 | 2004-2007 | France | 2 cycles of gemcitabine 1000 mg/m2 weekly for 3 wk; followed by 50.4 Gy radiotherapy and 300 mg/m2 gemcitabine weekly for two weeks |
S + ACT | 45 | 4 cycles of gemcitabine 1000 mg/m2 weekly for 3 wk | |||
Neoptolemos et al[25,28,29], 2001, 2004, 2009 (ESPAC-1) | S + ACDT | 73 | 1994-2000 | Europe | 2 courses of 20 Gy radiotherapy and 500 mg/m2 fluorouracil on days 1-3 |
S + ACT | 75 | 6 courses of fluorouracil 425 mg/m2 and folinic acid 20 mg/m2 daily for 5 d | |||
S + ACT + ACDT | 72 | 2 courses of 20 Gy radiotherapy and 500 mg/m2 fluorouracil on days 1-3; then 6 courses of fluorouracil 425 mg/m2 and folinic acid 20 mg/m2 daily for 5 d | |||
Surgery | 69 | ||||
ESPAC-1 plus | S + ACDT | 33 | 1994-2000 | Europe | 2 courses of 20 Gy radiotherapy and 500 mg/m2 fluorouracil on days 1–3 |
Surgery | 36 | ||||
S + ACT | 97 | 6 courses of fluorouracil 425 mg/m2 and folinic acid 20 mg/m2 daily for 5 d | |||
Surgery | 95 | ||||
ESPAC-3 (V1) | S + ACT | 61 | 1994-2000 | Europe | 6 courses of fluorouracil 425 mg/m2 and folinic acid 20 mg/m2 daily for 5 d |
Surgery | 61 |
- Citation: Shen P, Huang KJ, Zhang CZ, Xiao L, Zhang T. Surgery with adjuvant or neoadjuvant treatment vs surgery alone for resectable pancreatic cancer: A network meta-analysis. World J Meta-Anal 2019; 7(6): 309-322
- URL: https://www.wjgnet.com/2308-3840/full/v7/i6/309.htm
- DOI: https://dx.doi.org/10.13105/wjma.v7.i6.309